Microba Life Sciences Ltd - Asset Resilience Ratio
Microba Life Sciences Ltd (MAP) has an Asset Resilience Ratio of 11.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Microba Life Sciences Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Microba Life Sciences Ltd's Asset Resilience Ratio has changed over time. See Microba Life Sciences Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Microba Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAP market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.00 Million | 11.53% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$5.00 Million | 11.53% |
Asset Resilience Insights
- Moderate Liquidity: Microba Life Sciences Ltd has 11.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Microba Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Microba Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
INTERGRATED DIA.H DL 025
F:8I8 |
Diagnostics & Research | 7.34% |
|
Immunovia publ AB
ST:IMMNOV |
Diagnostics & Research | 83.99% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Annual Asset Resilience Ratio for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Microba Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.02% | AU$2.85 Million ≈ $2.02 Million |
AU$47.44 Million ≈ $33.56 Million |
-1.60pp |
| 2023-12-31 | 7.61% | AU$4.42 Million ≈ $3.13 Million |
AU$58.04 Million ≈ $41.07 Million |
-19.28pp |
| 2022-12-31 | 26.90% | AU$12.63 Million ≈ $8.94 Million |
AU$46.95 Million ≈ $33.22 Million |
+25.86pp |
| 2021-12-31 | 1.04% | AU$408.88K ≈ $289.31K |
AU$39.48 Million ≈ $27.93 Million |
+0.49pp |
| 2020-12-31 | 0.54% | AU$100.60K ≈ $71.18K |
AU$18.49 Million ≈ $13.08 Million |
+0.08pp |
| 2019-12-31 | 0.46% | AU$49.77K ≈ $35.22K |
AU$10.81 Million ≈ $7.65 Million |
-- |
| 2018-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$13.99 Million ≈ $9.90 Million |
-- |
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more